Edition:
United States

Exelixis Inc (EXEL.O)

EXEL.O on Nasdaq

8.76USD
27 Jul 2016
Change (% chg)

$0.12 (+1.39%)
Prev Close
$8.64
Open
$8.66
Day's High
$8.88
Day's Low
$8.66
Volume
4,750,578
Avg. Vol
5,405,119
52-wk High
$8.88
52-wk Low
$3.55

Select another date:

Fri, Jul 22 2016

BRIEF-Ipsen and Exelixis receive positive CHMP opinion for Cabometyx

* Ipsen and its partner Exelixis receive positive CHMP opinion for Cabometyx (cabozantinib) for treatment of advanced renal cell carcinoma in adults

BRIEF-Exelixis, Ipsen post results from advanced renal cell carcinoma study

* Exelixis and its partner Ipsen announce positive overall survival results from subgroup analyses of phase 3 trial of CABOMETYX(tm) (cabozantinib) tablets in advanced renal cell carcinoma at 2016 ASCO annual meeting

BRIEF-Exelixis and Ipsen announce Phase 3 trial results of CABOMETYX

* Announced on Sunday Phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Ipsen SA says Exelixis Inc reported positive top-line results from Cabosun phase 2 trial of Cabozantinib

* reported positive top line results from Cabosun phase 2 trial of Cabozantinib in patients with untreated advanced renal cell carcinoma

BRIEF-Exelixis reports Q1 loss per share $0.27

* Exelixis announces first quarter 2016 financial results and provides corporate update

BRIEF-Ipsen partner Exelixis obtains FDA approval of CABOMETYX tablets

* Announces that its partner Exelixis obtained FDA approval of CABOMETYX (cabozantinib) tablets for patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Exelixis gets FDA approval for Cabometyx tablets

* Exelixis announces FDA approval of Cabometyx(TM) (Cabozantinib) tablets for patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy

BRIEF-Exelixis and Ipsen enter into exclusive licensing agreement

* Exelixis and Ipsen enter into exclusive licensing agreement to commercialize and develop novel cancer therapy cabozantinib in regions outside the United States, Canada and Japan

Select another date: